When and How You Become Refractory to a Drug and How to Find the Best Next Treatment
Many patients wonder how one becomes refractory to a drug, and how the specialist knows what the next best step is to take. How long should you let your numbers increase without making a change in treatment? When is it ok to let it ride and for how long? And with all the different options, how can you truly know what your "next best option" really is? Learn the answers to these questions and more as we hear from myeloma specialist Dr. Omar Nadeem from Dana Farber Cancer Institute.
Audrey introduces the agenda of the event and featured speaker Dr. Omar Nadeem.
Dr. Omar Nadeem talks about how one becomes refractory to a drug, and how the specialist knows what the next best step is to take.
Type your questions in the chat and we will answer them!
Audrey Burton-Bethke
Audrey joined the HealthTree Foundation as the Myeloma Community Program Director in 2020. While not knowing much about myeloma at the start, she has since worked hard to educate herself, empathize and learn from others' experiences. She loves this job. Audrey is passionate about serving others, loves learning, and enjoys a nice mug of hot chocolate no matter the weather.
Omar Nadeem, MD
Dr. Omar Nadeem completed his internal medicine residency training at Dartmouth-Hitchcock Medical Center and his hematology/oncology fellowship at the Warren Alpert Medical School of Brown University. He joined the Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute in 2018. He is an assistant professor at Harvard Medical School and serves as the Clinical Director of Myeloma Cellular Therapies Program and Medical Director of Center for Early Detection and Interception of Blood Cancers the Dana-Farber Cancer Institute. His clinical and research interests include studying the role of immunotherapy and cellular therapies in multiple myeloma, with particular focus on CAR T therapy. He serves as a principal investigator of several clinical trials in smoldering multiple myeloma, newly diagnosed disease and relapsed and refractory multiple myeloma.